An update on benznidazole for the treatment of patients with Chagas disease.

• Autores: Ritesh P. Thakare, Arunava Dasgupta, Sidharth Chopra
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 54, Nº. 1, 2018, págs. 15-24
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Chagas disease is a vector-borne, systemic and chronic parasitic infection caused by Trypanosoma cruzi with approximately 8 million cases worldwide. The treatment for acute phase of Chagas disease consists of benznidazole and nifurtimox, although this treatment combination falls short in terms of efficacy against chronic phases of infection. This review provides an update on benznidazole progress and approval by the U.S. Food and Drug Administration in 2017 for the treatment of Chagas disease along with its lacunae